Metabolon Selected for Membership in NCI Research Group
News Dec 01, 2005
This is Metabolon’s second project with NCI but first project as a member of the EDRN will be a collaboration with the University of Michigan to discover disease biomarkers for prostate cancer.
"Membership in the EDRN is a great privilege," said Dr. John Ryals, president and CEO of Metabolon.
"Metabolon will be able to collaborate with other members to discover and develop biomarkers for the early diagnosis of cancers."
Metabolon will share its technology and metabolomics expertise with Dr. Arul Chinnaiyan of the University of Michigan on the prostate cancer project.
"Metabolon is at the forefront in the emerging area of metabolomics, and we are extremely excited about embarking on this collaboration," said Dr. Chinnaiyan.
"If metabolomic biomarkers can be identified for prostate cancer, Metabolon’s technology platform may have applications in other cancers as well."
Tight junctions are multi-protein complexes that serve as barriers in epithelial tissues such as the skin or lining of the gut. Loss of a specific tight junction barrier protein, claudin 18, occurs in the majority of gastric cancer patients and is correlated with poor prognosis in patients with advanced gastric cancer.READ MORE
Policies, economic systems, and marketing practices that promote the consumption of energy-dense, nutrient-poor food, changing behavioral patterns that couple high total energy intake with insufficient physical activity, and human-built environments that amplify these factors are driving a worldwide rise in excess body weight, according to a new report.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019